MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.380
+0.040
+1.71%
Closed 16:00 05/17 EDT
OPEN
2.340
PREV CLOSE
2.340
HIGH
2.380
LOW
2.300
VOLUME
359.00K
TURNOVER
--
52 WEEK HIGH
4.750
52 WEEK LOW
1.440
MARKET CAP
193.04M
P/E (TTM)
-15.0063
1D
5D
1M
3M
1Y
5Y
VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 05/06 00:45
VTv Therapeutics On May 4 Filed To Increase Number Of Shares Of Class A Common Stock Co Is Authorized To Issue From 100M Shares To 200M Shares
https://www.sec.gov/Archives/edgar/data/0001641489/000156459021024143/vtvt-8k_20210505.htm
Benzinga · 05/05 21:31
vTv Therapeutics EPS misses by $0.03, beats on revenue
vTv Therapeutics (VTVT): Q1 Non-GAAP EPS of -$0.09 misses by $0.03; GAAP EPS of -$0.08.Revenue of $1M beats by $0.6M.Shares +2.06% AH.Press Release
Seekingalpha · 05/05 21:08
10-Q: VTV THERAPEUTICS INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this Quarterly Report...
Edgar Online - (EDG = 10Q, 10K) · 05/05 20:41
vTv Therapeutics Q1 EPS $(0.08) Up From $(0.11) YoY
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.08) per share. This is a 27.27 percent increase over losses of $(0.11) per share from the same period last year.
Benzinga · 05/05 20:24
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes
GlobeNewswire · 05/05 20:10
-- Earnings Flash (VTVT) VTV THERAPEUTICS Posts Q1 Revenue $1M
MT Newswires · 05/05 16:51
Global Type 1 Diabetes Drug Forecast and Market Analysis Report 2021-2029 : Rise of Pump Usage and Increased Market Entry of Ultra-Rapid-Acting Insulin Formulations May Improve the Landscape
Dublin, April 21, Apr 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Type 1 Diabetes - Global Drug Forecast and...
GlobeNewswire · 04/21 11:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of VTV THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTVT stock price target is 6.75 with a high estimate of 7.50 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 3.02M
% Owned: 3.72%
Shares Outstanding: 81.11M
TypeInstitutionsShares
Increased
11
429.57K
New
4
26.88K
Decreased
7
28.72K
Sold Out
5
111.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Executive Director
Robin Abrams
President/Chief Executive Officer
Stephen Holcombe
Chief Financial Officer/Executive Vice President
Rudy Howard
Director
Hersh Kozlov
Director
Richard Nelson
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
No Data
  • All
  • Financials
  • Insiders
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.